Close Menu

Xencor said this week it has exclusively licensed its Xtend antibody technology to Merck.

The drug firm will use the technology to develop antibodies against an undisclosed drug target.

In return, Merck will pay Xencor a $3 million upfront license fee. It also will pay Xencor an undisclosed amount if it selects an Xtend variant, and pay undisclosed amounts in clinical development milestones and royalties on product sales.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Following its departure from the European Union, the UK is to implement a fast-track visa program aimed at attracting scientific talent to Britain, according to BBC News.

The Washington Post reports that researchers are quickly analyzing the coronavirus that has been causing illness and sharing their findings.

ScienceInsider reports that researchers in Brazil are concerned that a creationist was chosen to run the agency that oversees graduate study programs there.

In PLOS this week: common variant associated with BMI in Arctic populations, analysis of microRNA markers associated with being born small for gestational age, and more.